-

Kashiv BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced that Dr. Sandeep Athalye, Global Chief Executive Officer, and Dr. Paras Vasanani, Head of Business Development, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 14, 2026, at 11:00 a.m. PST.

44th Annual J.P. Morgan Healthcare Conference – Kashiv BioSciences Company Presentation
Date: Wednesday, January 14, 2026
Time: 11:00 - 11:25 a.m. PST
Location: Golden Gate Conference Room – The Westin St. Francis Hotel, San Francisco, California

About Kashiv BioSciences:
Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the USA, and its subsidiaries in India (together “Kashiv BioSciences”) operate together with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines. For more information, visit www.kashivbiosciences.com and follow us on LinkedIn.

Contacts

For further information or queries please contact:
Dr. Paras Vasanani
Head – Business Development
paras.vasanani@kashivbio.com

Heena Dhedhi
Head – Corporate Communications
heena.dhedhi@kashivbio.com

Industry:

Kashiv BioSciences, LLC

Release Versions
EnglishSpanishGermanFrenchItalianDutch

Contacts

For further information or queries please contact:
Dr. Paras Vasanani
Head – Business Development
paras.vasanani@kashivbio.com

Heena Dhedhi
Head – Corporate Communications
heena.dhedhi@kashivbio.com

More News From Kashiv BioSciences, LLC

Kashiv BioSciences Secures INR 648 Crore Financing from Union Bank of India to Expand Manufacturing Facilities in Gujarat, India

AHMEDABAD, India--(BUSINESS WIRE)--Kashiv BioSciences Private Limited (“Kashiv”), a biopharmaceutical company, today announced that it has secured financing of INR 648 crore from the Union Bank of India. The proceeds will be used to expand its state-of-the-art manufacturing facility in Pipan, near Ahmedabad, Gujarat. The new single-use commercial manufacturing facility will be one of India’s largest, equipped with cutting-edge technologies to support the production of high-quality biologics and...

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC, a fully-integrated biopharmaceutical company, announced that they have submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA), for ADL-018, a proposed biosimilar to XOLAIR® (omalizumab). The submissions are intended to seek approval in the United States and the European Economic Area, respectively....

Kashiv BioSciences and JAMP Pharma Corporation Announce the Launch of PEXEGRA® and FILRA® Biosimilars in Canada

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC today announced the commercial launch of PEXEGRA®, a biosimilar referencing Neulasta®, and FILRA®, a biosimilar referencing Neupogen®, in the Canadian market. Both biosimilars will be marketed in Canada through an exclusive agreement with JAMP Pharma Corporation. PEXEGRA® (6 mg/0.6 mL pre-filled syringe) and FILRA® (300 mcg/0.5 mL and 480 mcg/0.8 mL pre-filled syringe) are used to treat neutropenia, low neutrophils which are a type of w...
Back to Newsroom